Ionis: Price Slump Is An Opportunity To Buy The Pipeline
Photo by CROCOTHERY/iStock via Getty Images
Ionis Pharmaceuticals (IONS) is a leader in RNA therapies best known for Spinraza, which is licensed to Biogen (BIIB) and which generated $60 million in royalty revenue for Ionis in Q1 2021. Because of some negative drug trial data since January, Ionis’s stock price has fallen from over $60 per share to below $40 per share, closing on May 28 at $37.25.
Despite the negative news, Ionis has proven its RNA antisense technology (effectively the same as RNAi,…
